Tesamorelin
Also known as Egrifta, Egrifta SV, Egrifta WR, TH9507
A growth hormone-releasing hormone analogue approved in the US for one use: excess abdominal fat in adults with HIV and lipodystrophy.
Tesamorelin is a synthetic analogue of growth hormone-releasing hormone (GHRH), all 44 amino acids of the human hormone with a chemical group added at one end to make it more stable. Like CJC-1295 it acts upstream of growth hormone, but unlike CJC-1295 and ipamorelin it is an approved medicine. It is approved in the US for a single, narrow use, and it is not approved in the EU.
What it is
The US label describes tesamorelin as the 44 amino acid sequence of human growth hormone-releasing factor with a hexenoyl group, a six-carbon chain with a double bond at position 3, attached to the tyrosine at its N-terminal end, and gives a molecular weight, as free base equivalent, of 5135.9. FDA's substance registry also records the last residue as leucinamide. Its amino acids are the standard ones, but the hexenoyl group cannot be written in the one-letter code, so no sequence is shown on this page: the plain code would describe the unmodified hormone sequence, not tesamorelin.
Where it is approved
In the US it was approved on 10 November 2010 as Egrifta (approval letter), for the reduction of excess abdominal fat in HIV-infected patients with lipodystrophy. The 2 mg presentation was renamed Egrifta SV in 2019 (letter), and a new formulation, Egrifta WR, was approved on 25 March 2025 (letter). Both the Egrifta SV label and the Egrifta WR label state that it "is not indicated for weight loss management as it has a weight neutral effect."
In the EU, the application was withdrawn in 2012, after EMA's committee had reached the provisional view that it could not be approved (EMA). It was withdrawn, not refused. Only FDA and EMA were checked for this page.
What the trials measured
The approval rests on two randomised, placebo-controlled trials in adults with HIV on antiretroviral therapy who had accumulated abdominal fat. Their main measure was the area of visceral fat, the fat around the organs, on a single CT image. Visceral fat fell on tesamorelin and not on placebo, fat under the skin of the abdomen did not change significantly, and the effect disappeared when treatment stopped. These are fat-depot measures. The trials did not show fewer heart attacks, longer life or better health, and EMA's committee judged that the reduction had not been shown to be clinically meaningful.
Trials outside the approved use, in fatty liver disease with HIV, in obesity with reduced growth hormone secretion, and in cognition in older adults, are small and single. They are set out above, labelled as outside the indication.
No published trial has measured strength, athletic performance or ageing outcomes with tesamorelin. A trial in muscle wasting in COPD, designed to measure the change in lean body mass (NCT01388920), enrolled three people and was terminated, the registry says, "based on a non-safety related corporate decision." A trial of tesamorelin added to exercise, measuring physical function in older adults with HIV (NCT06554717), is recruiting.
The muscle claim most often made for tesamorelin traces to an exploratory analysis of the two approval trials. It included only patients whose visceral fat had fallen by at least 8%, so it is no longer a randomised comparison, and it found increases in lean muscle area on CT of 0.64 to 1.08 cm2 across four trunk muscle groups. FDA quoted a seller describing this as tesamorelin's ability to "increase muscle area in clinical studies" in one of the warning letters below.
What is not known
Its long-term safety. The label says long-term cardiovascular safety has not been established, and the two long-term studies FDA required at approval are recorded as terminated, with completion dates in 2018 and no results posted. The effects of raising IGF-1 for years are, in the label's words, unknown.
Sold outside prescription
In warning letters dated 24 August 2026, FDA named products sold as tesamorelin, among them a "Tesamorelin Ipamorelin Blend", as unapproved new drugs, writing that no approved applications are in effect for them (one such letter). The trials on this page tested tesamorelin on its own. An approved medicine and a product sold under its name are not the same thing: the trials and the label above describe the approved product, prescribed for its indication.
Anti-doping
WADA's Prohibited List names tesamorelin under S2.2.4, growth hormone releasing factors, prohibited at all times; the list was read in a browser by a person on 11 October 2026, because WADA's site refuses automated clients (source). Earlier second-hand accounts agree. A 2022 anti-doping laboratory paper describes tesamorelin among the prohibited growth hormone-releasing hormone analogues it was built to detect in urine.
What the research shows
Each statement below is labelled with the strongest kind of study supporting it, and links to that study.
- Meta-analysisSupportive / Moderate confidence
Pooled across trials in adults with HIV, tesamorelin reduced visceral, trunk and limb fat and waist circumference, and increased lean body mass, compared with placebo.
A 2026 meta-analysis of five randomised controlled trials of tesamorelin against placebo in adults with HIV found significant reductions in visceral adipose tissue, trunk fat, limb fat, hepatic fat percentage and waist circumference, a significant increase in lean body mass, and no significant change in subcutaneous fat or BMI. A second 2026 meta-analysis of four trials in HIV-associated lipodystrophy, 909 patients in all, reported reductions in visceral fat, waist circumference and trunk fat, an increase in lean body mass, and higher discontinuation on tesamorelin that did not reach statistical significance.
Pooled results from multiple human trials.
- Every pooled trial was in people with HIV. A gain in lean mass measured by body scan in this group is not a measure of strength or performance, and says nothing about people without HIV.
- The second meta-analysis notes limited data on long-term safety and on how long the effects last.
- Pooled estimates combine trials of different durations, so they are given here as directions rather than figures; the individual trials above carry the numbers with their arms and durations.
- The loss of limb fat is a reduction in fat under the skin of the arms and legs, which the individual trials reported as unchanged.
- Human randomised trialSupportive / Moderate confidence
In adults with HIV and excess abdominal fat, tesamorelin 2 mg reduced visceral fat measured by CT over 26 weeks, while it rose on placebo.
Study 1 randomised 412 patients with HIV (86% men) who had accumulated abdominal fat to tesamorelin 2 mg or placebo for 26 weeks. Visceral adipose tissue on computed tomography fell by 15.2% with tesamorelin and rose by 5.0% with placebo. Triglycerides fell by 50 mg per decilitre against a rise of 9, and IGF-I rose by 81.0% against a fall of 5.0%. Adverse events did not differ significantly, but more patients on tesamorelin withdrew because of one. No significant differences were seen in glycaemic measures.
Tested in humans under randomised, controlled conditions.
- Visceral fat area on a CT scan is a measure of one fat depot. It is not body weight, general fat loss or a health outcome; the trial did not show fewer heart attacks or longer life.
- Adults with HIV on antiretroviral therapy with abdominal fat accumulation. The results do not describe people without HIV.
- The figures come from the published abstract only, which does not state a funder.
- Human randomised trialSupportive / Moderate confidence
A second randomised trial of 404 patients with HIV found the same direction of effect on visceral fat over 6 months, with no change in limb or subcutaneous abdominal fat.
Study 2 randomised 404 HIV-infected patients with excess abdominal fat, 2:1, to tesamorelin 2 mg or placebo. Over the 6-month efficacy phase, visceral adipose tissue fell by 10.9% (21 cm2) with tesamorelin against 0.6% (1 cm2) with placebo. Trunk fat, waist circumference and waist-hip ratio improved, with no change in limb or subcutaneous abdominal fat. IGF-I increased, with no change in glucose parameters.
Tested in humans under randomised, controlled conditions.
- The same fat-depot endpoint as Study 1, in the same population.
- The figures come from the published abstract only, which does not state a funder.
- Human randomised trialSupportive / Moderate confidence
Visceral fat came back when tesamorelin was stopped.
In the extension phases of both trials, patients who had taken tesamorelin for 26 weeks were re-randomised to continue it or switch to placebo. In those who continued, the reduction in visceral fat was maintained at 52 weeks. In those switched to placebo, the authors of Study 1's extension report that visceral fat reaccumulated, and the authors of Study 2 that the initial improvements were rapidly lost.
Tested in humans under randomised, controlled conditions.
- The effect lasts only as long as treatment, in the authors' words: these effects do not last beyond the duration of treatment.
- Human randomised trialSupportive / Low confidence
Outside its approved use, tesamorelin reduced liver fat in people with HIV and fatty liver disease over 12 months.
A randomised, double-blind trial enrolled 61 people with HIV and a hepatic fat fraction of 5% or more and assigned them 1:1 to tesamorelin 2 mg or placebo for 12 months. Liver fat fell more with tesamorelin, an absolute effect of -4.1% (95% CI -7.6 to -0.7), a 37% relative reduction. After 12 months, 35% on tesamorelin and 4% on placebo had a hepatic fat fraction below 5%. Fasting glucose and HbA1c did not differ between groups.
Tested in humans under randomised, controlled conditions.
- Not an approved indication. One small trial; the authors say further studies are needed on long-term effects on liver histology.
- Funded by the National Institutes of Health.
- Human randomised trialSupportive / Low confidence
Outside its approved use, in 60 people with abdominal obesity and reduced growth hormone secretion, tesamorelin reduced visceral fat over 12 months.
A randomised, double-blind trial gave tesamorelin 2 mg or placebo for 12 months to 60 abdominally obese people with reduced growth hormone secretion. Visceral fat changed by -16 against +19 cm2, a treatment effect of -35 cm2 (95% CI -58 to -12), with no significant effect on subcutaneous abdominal fat. Carotid intima-media thickness, C-reactive protein and triglycerides improved, with no change in glucose measures and no serious adverse events.
Tested in humans under randomised, controlled conditions.
- Not an approved indication, and a selected group with reduced growth hormone secretion, not obesity in general.
- Intima-media thickness and C-reactive protein are risk markers, not cardiovascular events.
- Human randomised trialSupportive / Low confidence
Outside its approved use, 20 weeks of tesamorelin had a favourable effect on cognitive test scores in older adults, with and without mild cognitive impairment.
A randomised, double-blind trial enrolled 152 adults aged 55 to 87, 66 of them with mild cognitive impairment, and gave tesamorelin 1 mg or placebo for 20 weeks. The intention-to-treat analysis showed a favourable effect on cognition (P = .03), similar in both groups, driven by executive function. IGF-I rose by 117% and percent body fat fell by 7.4%. Adverse events, described as mild, were reported by 68% on tesamorelin and 36% on placebo.
Tested in humans under randomised, controlled conditions.
- Not an approved indication. A single 20-week trial with composite test scores; the authors call for longer trials.
- Human randomised trialNo effect found / Low confidence
In people with HIV, abdominal obesity and cognitive impairment, 6 months of tesamorelin did not improve cognition more than standard care.
An open-label phase 2 trial randomised 73 people, 3:2, to tesamorelin or standard of care for 6 months. The between-group difference in neurocognitive performance was not significant (P = .673), although waist circumference fell more with tesamorelin (median difference -2.7 cm).
Tested in humans under randomised, controlled conditions.
- Open label, no placebo, and, in the authors' words, insufficient power.
Reported and theoretical risks
- Human RCTmoderate
Glucose intolerance and diabetes
In the phase 3 trial abstracts, glycaemic measures did not differ significantly from placebo over 26 weeks. In a smaller randomised trial in adults with HIV, fasting glucose rose more on tesamorelin than on placebo at 2 weeks (treatment effect 7 mg/dL, 95% CI 1 to 14) but not over 6 months overall. In older adults with mild cognitive impairment, tesamorelin increased fasting insulin by 35%, within the normal range. The US labels, pooling the clinical trials as label data, report that patients on tesamorelin had an increased risk of developing diabetes (HbA1c of 6.5% or more) compared with placebo, 5% against 1%, with a hazard ratio of 3.3 (CI 1.4 to 9.6), and carry a warning that glucose intolerance or diabetes may develop. Those trials excluded people who already had type 1 or type 2 diabetes.
- Metamild
Joint and muscle pain, fluid retention and injection-site reactions
A 2026 meta-analysis of the randomised trials associates tesamorelin with arthralgia, myalgia, paresthesia and injection-site reactions such as erythema. The US label lists arthralgia, injection-site erythema and pruritus, pain in extremity, peripheral oedema and myalgia as the most common adverse reactions, and warns of fluid retention, which may include oedema, arthralgia and carpal tunnel syndrome, and of hypersensitivity reactions.
- Mechanismunknown
Raised IGF-1, of unknown long-term effect, and malignancy
The US label states that tesamorelin increases serum IGF-1, a growth factor, that the effects of prolonged elevations are unknown, and that IGF-1 should be monitored. It warns of an increased risk of neoplasms, contraindicates use with active malignancy, and also contraindicates it in pregnancy and in people with disruption of the hypothalamic-pituitary axis. EMA's committee called the IGF-1 increase a major safety concern, noting that high IGF-1 may be associated with an increased risk of cancer and a potential worsening of diabetic eye disease.
- Mechanismunknown
Long-term safety not established; the required long-term studies were terminated
The US label states that long-term cardiovascular safety has not been established. At approval in 2010, FDA required a long-term observational safety study of at least 10 years and a clinical trial on diabetic retinopathy. Both are recorded on ClinicalTrials.gov as terminated, with completion dates in August 2018, no reason given and no results posted.
Regulatory status
Status differs by country and changes over time. Each entry is dated and sourced.
USFDAapproved limited indication
Initial US approval 2010, as Egrifta. The current Egrifta WR label, revised 3/2025, gives one indication: the reduction of excess abdominal fat in HIV-infected adult patients with lipodystrophy. Its limitations of use state that long-term cardiovascular safety has not been established, that it is not indicated for weight loss management, and that there are no data to support improved compliance with antiretroviral therapy. No boxed warning.
As of 25 March 2025. Source
EUEMAnot approved
The applicant withdrew its marketing authorisation application on 21 June 2012. At that time EMA's committee was of the provisional opinion that Egrifta could not have been approved, citing difficulty separating lipodystrophy fat from obesity fat, a benefit not shown to be clinically meaningful, trial patients unrepresentative of European patients, and the IGF-1 increase as a major safety concern.
As of 12 July 2012. Source
internationalWADAbanned in sport
Named in WADA's Prohibited List under S2.2.4, growth hormone releasing factors, among "growth hormone-releasing hormone (GHRH) and its analogues". Section S2 is prohibited at all times, and its substances are non-Specified. The list was read in a browser by a person on 11 October 2026, because WADA's site refuses automated clients; the pasted text does not state the list's year.
As of 11 October 2026. Source
Research and analysis
Related peptides
- CJC-1295A synthetic analogue of growth hormone-releasing hormone
- IpamorelinA synthetic growth hormone secretagogue
Sources
- 1. Falutz J et al. Metabolic effects of a growth hormone-releasing factor in patients with HIV.. The New England Journal of Medicine. 2007. PubMed 18057338
- 2. Falutz J et al. Effects of tesamorelin, a growth hormone-releasing factor, in HIV-infected patients with abdominal fat accumulation: a randomized placebo-controlled trial with a safety extension.. Journal of Acquired Immune Deficiency Syndromes. 2010. PubMed 20101189
- 3. Falutz J et al. Long-term safety and effects of tesamorelin, a growth hormone-releasing factor analogue, in HIV patients with abdominal fat accumulation.. AIDS. 2008. PubMed 18690162
- 4. Badran AS et al. Body composition, hepatic fat, metabolic, and safety outcomes of Tesamorelin, a GHRH analogue, in HIV-associated lipodystrophy: A meta-analysis of randomized controlled trials.. Obesity Research & Clinical Practice. 2026. PubMed 41545261
- 5. Ditta AM et al. Efficacy and Safety of Tesamorelin in People Living With HIV (PLWH) With Lipodystrophy: A Systematic Review and Meta-Analysis.. Journal of the International Association of Providers of AIDS Care. 2026. PubMed 42538058(open access)
- 6. Stanley TL et al. Effects of tesamorelin on non-alcoholic fatty liver disease in HIV: a randomised, double-blind, multicentre trial.. The Lancet HIV. 2019. PubMed 31611038(open access)
- 7. Makimura H et al. Metabolic effects of a growth hormone-releasing factor in obese subjects with reduced growth hormone secretion: a randomized controlled trial.. The Journal of Clinical Endocrinology & Metabolism. 2012. PubMed 23015655(open access)
- 8. Baker LD et al. Effects of growth hormone-releasing hormone on cognitive function in adults with mild cognitive impairment and healthy older adults: results of a controlled trial.. Archives of Neurology. 2012. PubMed 22869065(open access)
- 9. Ellis RJ et al. Effects of Tesamorelin on Neurocognitive Impairment in Persons With HIV and Abdominal Obesity.. The Journal of Infectious Diseases. 2025. PubMed 39813152
- 10. Stanley TL et al. Effect of tesamorelin on visceral fat and liver fat in HIV-infected patients with abdominal fat accumulation: a randomized clinical trial.. JAMA. 2014. PubMed 25038357(open access)
- 11. EGRIFTA WR (tesamorelin) for injection. Prescribing Information, revised 3/2025 (application 022505). U.S. Food and Drug Administration, Drugs@FDA. 2025. View source(open access)
- 12. Questions and answers: Withdrawal of the marketing authorisation application for Egrifta (tesamorelin), 12 July 2012 (EMA/CHMP/475021/2012). European Medicines Agency. 2012. View source(open access)
- 13. NDA 022505 approval letter, Egrifta (tesamorelin for injection), November 10, 2010. U.S. Food and Drug Administration. 2010. View source(open access)
- 14. Long-term Observational Study in HIV Subjects Exposed to EGRIFTA®. ClinicalTrials.gov. 2018. NCT01579695(open access)
- 15. Diabetic Retinopathy in HIV Subjects Treated With EGRIFTA®. ClinicalTrials.gov. 2018. NCT01591902(open access)
- 16. The Prohibited List, World Anti-Doping Agency. World Anti-Doping Agency. 2026. View source(open access)